Home Business Gilead quarterly income rises 26% on remdesivir gross sales By Reuters

Gilead quarterly income rises 26% on remdesivir gross sales By Reuters

134
0


© Reuters. Gilead Sciences Inc pharmaceutical firm is seen through the outbreak of the coronavirus illness (COVID-19), in California

(Reuters) – Gilead Sciences Inc (NASDAQ:) posted a 26% rise in quarterly income that topped Wall Road estimates on Thursday, helped by gross sales of its antiviral drug, remdesivir, which is allowed to deal with COVID-19 sufferers the world over.

Remdesivir introduced in $1.9 billion within the fourth quarter ended Dec. 31, above analysts’ estimates of $1.34 billion, in keeping with Refinitiv IBES information.

Shares of Gilead have been up 2.5% in prolonged buying and selling.

The corporate forecast fiscal 2021 outcomes largely forward of analyst expectations and raised its dividend by 4.4%.

Fourth-quarter income totaled $7.42 billion, beating the typical analyst estimate of $7.33 billion.

Gilead projected fiscal 2021 product gross sales of $23.7 billion to $25.1 billion, forward of the Wall Road consensus of $24.27 billion in income, in keeping with IBES information from Refinitiv.

Disclaimer: Fusion Media wish to remind you that the information contained on this web site will not be essentially real-time nor correct. All CFDs (shares, indexes, futures) and Foreign exchange costs usually are not offered by exchanges however fairly by market makers, and so costs might not be correct and should differ from the precise market value, which means costs are indicative and never applicable for buying and selling functions. Subsequently Fusion Media doesn`t bear any duty for any buying and selling losses you may incur on account of utilizing this information.

Fusion Media or anybody concerned with Fusion Media is not going to settle for any legal responsibility for loss or injury on account of reliance on the knowledge together with information, quotes, charts and purchase/promote indicators contained inside this web site. Please be absolutely knowledgeable relating to the dangers and prices related to buying and selling the monetary markets, it is likely one of the riskiest funding kinds attainable.